Medical Community Supports Absorption Pharmaceuticals Latest $1 Million Raise

Share Article

Absorption Pharmaceuticals (AP), LLC. recently raised approximately $1 million of new investment from esteemed members of the medical community. The raise will go towards two, new second source manufacturing sites needed to meet the growing demand for AP’s product, PROMESCENT, the over-the-counter topical treatment for Premature Ejaculation (PE).

Absorption Pharmaceuticals (AP), LLC. recently raised approximately $1 million of new investment from esteemed members of the medical community. The raise will go towards two, new second source manufacturing sites needed to meet the growing demand for AP’s product, PROMESCENT, the over-the-counter topical treatment for Premature Ejaculation (PE). Sales of the FDA approved PROMESCENT have been the company’s best for 10 consecutive months. The company sees this trend continuing with the growth rate accelerating.

The additional funding will also be put towards strengthening AP’s sales force and operations in order to increase the sales momentum and target the dramatically underserved market of more than 30 million sufferers of Premature Ejaculation in the US alone.

AP is receiving overwhelming support from within the medical community both in the US and globally. Top urologists, sexual medicine experts and thought leaders in the US recently met in Chicago for AP’s first Board of Advisors meeting. All members showed enormous support and confidence in the effectiveness of PROMESCENT as a treatment for PE and AP’s bold plans for the future. http://promescent.com/advisory-board.

For additional media related information please contact:
May Lee/Media Consultant
Absorption Pharmaceuticals
310-367-9500
may(at)lotusmediahouse.com
http://www.promescent.com    

About Absorption Pharmaceuticals (AP), LLC.

Absorption Pharmaceuticals (AP), LLC., founded in 2008 and based in Newport Beach, CA, is the manufacturer of PROMESCENT. The FDA approved treatment under strict monograph guidelines was developed by Dr. Ronald Gilbert, Urologist, Founder and Chief Medical Officer of Absorption Pharmaceuticals. The lidocaine based topical anesthetic utilizes a patented, advanced, transcutaneous absorption technology. Since PROMESCENT’S formal introduction in 2011, it has been enthusiastically embraced by leading experts in the field of sexual medicine and practicing urologists globally. PROMESCENT is currently sold in 42 countries and counting. AP is developing additional international distribution partnerships to continue dramatic sales growth in the coming months. The company’s mission is to be the leader in bringing awareness to the pervasive issue of premature ejaculation and providing the best, most effective treatment available. For general information or product inquires email questions to: info@promescent.com

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website